Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.

Im J, Islam MT, Ahmmed F, Kim DR, Chon Y, Zaman K, Khan AI, Ali M, Marks F, Qadri F, Clemens JD.

PLoS Negl Trop Dis. 2019 Mar 14;13(3):e0007179. doi: 10.1371/journal.pntd.0007179. eCollection 2019 Mar.

2.

Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.

Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Han SH, Attridge S, Donner A, Ganguly NK, Bhattacharya SK, Nair GB, Clemens JD, Lopez AL.

PLoS Negl Trop Dis. 2011 Oct;5(10):e1289. doi: 10.1371/journal.pntd.0001289. Epub 2011 Oct 18.

3.

Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.

Qadri F, Ali M, Lynch J, Chowdhury F, Khan AI, Wierzba TF, Excler JL, Saha A, Islam MT, Begum YA, Bhuiyan TR, Khanam F, Chowdhury MI, Khan IA, Kabir A, Riaz BK, Akter A, Khan A, Asaduzzaman M, Kim DR, Siddik AU, Saha NC, Cravioto A, Singh AP, Clemens JD.

Lancet Infect Dis. 2018 Jun;18(6):666-674. doi: 10.1016/S1473-3099(18)30108-7. Epub 2018 Mar 14.

4.

5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.

Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dhingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD.

Lancet Infect Dis. 2013 Dec;13(12):1050-6. doi: 10.1016/S1473-3099(13)70273-1. Epub 2013 Oct 18. Erratum in: Lancet Infect Dis. 2013 Dec;13(12):1011.

PMID:
24140390
5.

Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.

Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F.

Vaccine. 2009 Feb 25;27(9):1386-92. doi: 10.1016/j.vaccine.2008.12.041. Epub 2009 Jan 13.

PMID:
19146897
6.

Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N, et al.

Lancet. 1990 Feb 3;335(8684):270-3.

PMID:
1967730
7.

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.

Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD.

Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8. Erratum in: Lancet. 2010 Oct 23;376(9750):1392.

PMID:
19819004
8.

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.

Capeding MRZ, Gonzales MLAM, Dhingra MS, D'Cor NA, Midde VJ, Patnaik BN, Thollot Y, Desauziers E.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2232-2239. doi: 10.1080/21645515.2017.1342908.

9.

Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.

Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Asaduzzaman M, Akter A, Khan A, Begum YA, Bhuiyan TR, Khanam F, Chowdhury MI, Islam T, Chowdhury AI, Rahman A, Siddique SA, You YA, Kim DR, Siddik AU, Saha NC, Kabir A, Cravioto A, Desai SN, Singh AP, Clemens JD.

N Engl J Med. 2016 May 5;374(18):1723-32. doi: 10.1056/NEJMoa1510330.

10.

A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.

Desai SN, Akalu Z, Teshome S, Teferi M, Yamuah L, Kim DR, Yang JS, Hussein J, Park JY, Jang MS, Mesganaw C, Taye H, Beyene D, Bedru A, Singh AP, Wierzba TF, Aseffa A.

Am J Trop Med Hyg. 2015 Sep;93(3):527-533. doi: 10.4269/ajtmh.14-0683. Epub 2015 Jun 15.

11.

Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design.

Ali M, You YA, Sur D, Kanungo S, Kim DR, Deen J, Lopez AL, Wierzba TF, Bhattacharya SK, Clemens JD.

Vaccine. 2016 Jan 20;34(4):479-485. doi: 10.1016/j.vaccine.2015.12.004. Epub 2015 Dec 17.

PMID:
26707378
12.

Exclusion of clinically atypical or microbiologically mixed diarrhoeal episodes from outcome events in a field trial of oral cholera vaccines.

Clemens JD, Stanton BF, Harris JR, Chakraborty J, Sack DA, Rao MR, Ahmed F, Ansaruzzaman M, Yunus MD, Svennerholm AM, et al.

Int J Epidemiol. 1989 Jun;18(2):440-5.

PMID:
2767860
13.

Field trial of oral cholera vaccines in Bangladesh.

Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, Stanton BF, Kay BA, Khan MU, Yunus M, Atkinson W, et al.

Lancet. 1986 Jul 19;2(8499):124-7.

PMID:
2873397
14.

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.

Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PV, Rao MR.

Lancet. 1997 Jan 25;349(9047):231-5.

PMID:
9014909
15.

Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F.

Vaccine. 2011 Oct 26;29(46):8285-92. doi: 10.1016/j.vaccine.2011.08.108. Epub 2011 Sep 9.

PMID:
21907255
16.

Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.

Clemens J, Rao M, Sack D, Ahmed F, Khan MR, Chakraborty J, Kay B, Huda S, Yunus M, van Loon F, et al.

Am J Epidemiol. 1995 Oct 1;142(7):759-64.

PMID:
7572947
17.

Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. II. Field evaluation of cross-protection against other members of the Vibrionaceae family.

Clemens JD, Harris JR, Kay BA, Chakraborty J, Sack DA, Ansaruzzaman M, Rahman R, Stanton BF, Khan MU, Khan MR, et al.

Vaccine. 1989 Apr;7(2):117-20.

PMID:
2665350
18.

Biomarkers of Environmental Enteropathy are Positively Associated with Immune Responses to an Oral Cholera Vaccine in Bangladeshi Children.

Uddin MI, Islam S, Nishat NS, Hossain M, Rafique TA, Rashu R, Hoq MR, Zhang Y, Saha A, Harris JB, Calderwood SB, Bhuiyan TR, Ryan ET, Leung DT, Qadri F.

PLoS Negl Trop Dis. 2016 Nov 8;10(11):e0005039. doi: 10.1371/journal.pntd.0005039. eCollection 2016 Nov.

19.

Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.

Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, Franke MF, Saha A, Yu Y, Kováč P, Calderwood SB, Ryan ET, LaRocque RC, Almazor CP, Qadri F, Ivers LC, Harris JB.

PLoS Negl Trop Dis. 2014 May 1;8(5):e2828. doi: 10.1371/journal.pntd.0002828. eCollection 2014 May.

20.

The design and analysis of cholera vaccine trials: recent lessons from Bangladesh.

Clemens J, Sack D, Rao M, Chakraborty J, Kay B, Ahmed F, Khan MR, van Loon FP, Svennerholm AM, Holmgren J.

Int J Epidemiol. 1993 Aug;22(4):724-30.

PMID:
8225749

Supplemental Content

Support Center